Azithromycin effects on lung microbiome in COPD patient
Ontology highlight
ABSTRACT: Azithromycin (AZM) reduces pulmonary inflammation and exacerbations in chronic obstructive pulmonary disease patients with emphysema. The antimicrobial effects of AZM on the lung microbiome are not known and may contribute to its beneficial effects. Methods. Twenty smokers with emphysema were randomized to receive AZM 250 mg or placebo daily for 8 weeks. Bronchoalveolar lavage (BAL) was performed at baseline and after treatment. Measurements included: rDNA gene quantity and sequence. Results. Compared with placebo, AZM did not alter bacterial burden but reduced α-diversity, decreasing 11 low abundance taxa, none of which are classical pulmonary pathogens. Conclusions. AZM treatment the lung microbiome
ORGANISM(S): human lung metagenome
PROVIDER: GSE74396 | GEO | 2016/07/19
SECONDARY ACCESSION(S): PRJNA300280
REPOSITORIES: GEO
ACCESS DATA